



## INDEPENDENT LIMITED ASSURANCE STATEMENT

To: The Stakeholders of AstraZeneca Plc

### Introduction and objectives of work

Bureau Veritas UK Limited (Bureau Veritas) has been engaged by AstraZeneca Plc (AstraZeneca) to provide limited assurance over sustainability activities reported in its 2019 Annual Report and form 20-F. This Assurance Statement applies to the related information included within the scope of work described below.

### Selected information

The scope of our work was limited to assurance over the information included within the following sections of the 2019 Annual Report and form 20-F ('the Report') for the period 1st of January to the 31st of December 2019 (the "Selected Information"):

- Key Performance Indicators - Be a Great Place to Work;
- Bioethics, including Clinical trials, Patient safety, Research use of human biological samples and Animal research;
- Emerging market healthcare;
- Responsible sales and marketing;
- Anti-bribery and anti-corruption;
- Transparency reporting;
- Responsible supply chain;
- Environmental protection, including Greenhouse gas emissions reduction, Energy use, Waste management, Water stewardship, Product environmental stewardship and Pharmaceuticals in the environment;
- Human rights;
- Managing change;
- Employee relations;
- Safety, health and wellbeing;
- Access to healthcare, including Healthy Lung, Healthy Heart, Young Health Programme and Responsible R&D
- Community investment, including Product donation programmes and Health and the environment;
- Sustainability, including Governance, Benchmarking and assurance, Our approach and Our Sustainability strategy;
- Greenhouse gas (GHG) reporting.

### Reporting Criteria

The Selected Information has been prepared in accordance with internal definitions set by AstraZeneca in their sustainability strategy to track and monitor their progress. The definitions for AstraZeneca's GHG reporting are aligned with the Greenhouse Gas Protocol Corporate Accounting and Reporting Standard (revised edition), as set out in the "Greenhouse gas (GHG) reporting" section of the Report.



## Limitations and Exclusions

Excluded from the scope of our work is any verification of information relating to:

- Activities outside the defined verification period;
- Positional statements (expressions of opinion, belief, aim or future intention by AstraZeneca) and statements of future commitment;
- Financial data taken from the Report which are audited by an external financial auditor, including but not limited to any statements relating to production, tax, sales, and financial investments; and
- Other information included in the Report other than scope defined above.

This limited assurance engagement relies on a risk based selected sample of sustainability data and the associated limitations that this entails. This independent statement should not be relied upon to detect all errors, omissions or misstatements that may exist.

## Responsibilities

The preparation and presentation of the Selected Information in the Report is the sole responsibility of the management of AstraZeneca.

Bureau Veritas was not involved in the drafting of the Report. Our responsibilities were to:

- Obtain limited assurance about whether the Selected Information has been appropriately and accurately prepared;
- Form an independent conclusion based on the assurance procedures performed and evidence obtained; and
- Report our conclusions to the Directors of AstraZeneca.

## Assessment Standard

We performed our work in accordance with International Standard on Assurance Engagements (ISAE) 3000 (Revised), Assurance Engagements Other than Audits or Reviews of Historical Financial Information, and in accordance with the main requirements of ISO 14064:2006 Part 3 - Specification with Guidance for the Validation and Verification of Greenhouse Gas Assertions.

## Summary of work performed

As part of its independent verification, Bureau Veritas undertook the following activities:

1. Assessed the appropriateness and accuracy of the Selected Information;
2. Conducted interviews with relevant personnel of AstraZeneca;
3. Carried out four site visits, selected employing a risk-based approach, in the following sites: Macclesfield - UK, Gaithersburg - US, Gothenburg - Sweden and Wuxi -China;



4. Reviewed the data collection and consolidation processes used to compile the Selected Information, including assessing assumptions made, the data scope and reporting boundaries;
5. Reviewed documentary evidence provided by AstraZeneca;
6. Reperformed a selection of aggregation calculations of the Selected Information;
7. Agreed a selection of the Selected Information to the corresponding source documentation; and
8. Reviewed the current sustainability issues that could affect AstraZeneca and are of interest to stakeholders.

## Conclusion

On the basis of our methodology and the activities described above, nothing has come to our attention to indicate that the Selected Information has not been properly prepared, in all material respects.

## Statement of Independence, Integrity and Competence

Bureau Veritas is an independent professional services company that specialises in quality, environmental, health, safety and social accountability with over 185 years' history. Its assurance team has extensive experience in conducting verification over environmental, social, ethical and health and safety information, systems and processes.

Bureau Veritas operates a certified<sup>1</sup> Quality Management System which complies with the requirements of ISO 9001:2015 and accordingly maintains a comprehensive system of quality control including documented policies and procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

Bureau Veritas has implemented and applies a Code of Ethics, which meets the requirements of the International Federation of Inspections Agencies (IFIA)<sup>2</sup> across the business to ensure that its employees maintain integrity, objectivity, professional competence and due care, confidentiality, professional behaviour and high ethical standards in their day-to-day business activities.

The assurance team for this work does not have any involvement in any other Bureau Veritas projects with AstraZeneca.

## Bureau Veritas UK Limited

London

12 February 2020

---

<sup>1</sup> Certificate available on request

<sup>2</sup> International Federation of Inspection Agencies – Compliance Code – Third Edition